Abstract
Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.
| Original language | English |
|---|---|
| Pages (from-to) | 423-427 |
| Number of pages | 5 |
| Journal | Tumori |
| Volume | 93 |
| Issue number | 5 |
| Publication status | Published - Sep 2007 |
Fingerprint
Keywords
- Chemotherapy
- Mesenchymal chondrosarcoma
- Radiotherapy
ASJC Scopus subject areas
- Cancer Research
Cite this
Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. / Cesari, Marilena; Bertoni, Franco; Bacchini, Patrizia; Mercuri, Mario; Palmerini, Emanuela; Ferrari, Stefano.
In: Tumori, Vol. 93, No. 5, 09.2007, p. 423-427.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution
AU - Cesari, Marilena
AU - Bertoni, Franco
AU - Bacchini, Patrizia
AU - Mercuri, Mario
AU - Palmerini, Emanuela
AU - Ferrari, Stefano
PY - 2007/9
Y1 - 2007/9
N2 - Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.
AB - Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.
KW - Chemotherapy
KW - Mesenchymal chondrosarcoma
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=36749002082&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749002082&partnerID=8YFLogxK
M3 - Article
VL - 93
SP - 423
EP - 427
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 5
ER -